SCHEMBL6090914

SCHEMBL6090914

CON=C1CCN2c3c(cccc31)C(=O)NC2c1ccc(OC)c(O)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
AR P10275 1/20 0.39
GAA P10253 3/20 0.38
KDM4E B2RXH2 9/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
MAPK1 P28482 2/20 0.37
LMNA P02545 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
ALDH1A1 P00352 7/20 0.37
HPGD P15428 4/20 0.37
HSD17B10 Q99714 2/20 0.36
CYP19A1 P11511 3/20 0.36
TP53 P04637 2/20 0.36
CYP3A4 P08684 2/20 0.36
XDH P47989 2/20 0.36
ATM Q13315 2/20 0.36
RAB9A P51151 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6090909 1.00 MAPT (0.40) MAPTMEN1KMT2AL3MBTL1AR
SCHEMBL6091800 0.91 ALDH1A1 (0.44) MAPTKMT2AGAAKDM4ESMN1; SMN2
SCHEMBL6091794 0.91 ALDH1A1 (0.44) MAPTKMT2AGAAKDM4ESMN1; SMN2
SCHEMBL6089910 0.89 GAA (0.39) MAPTMEN1KMT2AGAAKDM4E
SCHEMBL6090310 0.87 MAPT (0.43) MAPTMEN1KMT2AL3MBTL1AR
SCHEMBL6090687 0.84 KDM4E (0.46) MAPTMEN1KMT2AL3MBTL1AR
SCHEMBL6089511 0.82 KDM4E (0.38) MAPTKMT2AGAAKDM4ESMN1; SMN2
SCHEMBL6089506 0.82 KDM4E (0.38) MAPTKMT2AGAAKDM4ESMN1; SMN2
SCHEMBL6090978 0.81 KDM4E (0.37) MAPTGAAKDM4ESMN1; SMN2TDP1
SCHEMBL6090982 0.81 KDM4E (0.37) MAPTGAAKDM4ESMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004028-A1 Novel PARP inhibitor MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1582520-A1 NOVEL PARP INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2005-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004028-A1 Novel PARP inhibitor PARP1, PARP2, PARP11 MAPT 497/4885MEN1 2771/4885KMT2A 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.